NOVOBN Stock Chart & Stats
$890.77
$0.00(0.00%)
At close: 4:00 PM EDT
$890.77
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$630.00 - $1,222.00
Previous CloseN/A
Volume0.00
Average Volume (3M)55.00
Market Cap
$3.63T
Enterprise Value$1.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)11.2
Beta-0.03
Next Earnings
Nov 04, 2026EPS Estimate
13.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.47
Shares Outstanding3,390,128,000
10 Day Avg. Volume35
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$789.28Price Target Upside-11.39% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novo Nordisk News
NOVOBN FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $630.00 and its highest was $1222.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $3.63T.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 89 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 04, 2026. The company reported $16.467 earnings per share for the quarter, beating the consensus estimate of $13.403 by $3.064.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 13.35.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $16.467 in its last earnings report, beating expectations of $13.403. Following the earnings report the stock price went down -5.119%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in MX:NOVOBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novo Nordisk
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NOVOBN Stock 12 Month Forecast
Average Price Target
$789.28
▼(-11.39% Downside)